Journal article
Achievements and obstacles of remyelinating therapies in multiple sclerosis
M Stangel, T Kuhlmann, PM Matthews, TJ Kilpatrick
Nature Reviews Neurology | NATURE PUBLISHING GROUP | Published : 2017
Abstract
Remyelination in the CNS is the natural process of damage repair in demyelinating diseases such as multiple sclerosis (MS). However, remyelination becomes inadequate in many people with MS, which results in axonal degeneration and clinical disability. Enhancement of remyelination is a logical therapeutic goal; nevertheless, all currently licensed therapies for MS are immunomodulatory and do not support remyelination directly. Several molecular pathways have been identified as potential therapeutic targets to induce remyelination, and some of these have now been assessed in proof-of-concept clinical trials. However, trial design faces several obstacles: optimal clinical or paraclinical outcom..
View full abstractGrants
Awarded by Biogen
Funding Acknowledgements
This study was supported by grants to T.K. from the German Research Foundation (SFB-TR128-B7; Ku1477/6-1) and the Interdisciplinary Clinical Research Center, Munster (IZKF; KuT3/012/15). P.M.M. is in receipt of personal and research support from the Edmond J. Safra Foundation and Lily Safra, the Imperial College National Institute for Health Research (NIHR) Biomedical Research Centre, the NIHR Senior Investigator Programme, the UK Dementia Research Institute, the UK Medical Research Council, Biogen and the Engineering and Physics Science Research Council. M.S. is supported by Niedersachsen Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony.